动物造模,压力性尿失禁 z-bio 2022-11-14 546

　　Objective: To study the effect of TGF-β1 gene therapy on rat model of postpartum stress urinary incontinence, and to explore the ideal new non-surgical treatment method for the disease.

　　METHODS: 240 SD female mice were modeled by hydrocystovaginal dilation method, 148 were randomly selected from 185 successful models and divided into 5 groups, which were treated with TGF-β1 gene therapy, ammoniacal drug therapy, electrical stimulation therapy, Empty plasmid vector injection and no treatment, in addition, 20 unconstructed rat models were selected as blank control, and sneeze experiment, urodynamic test, and pelvic floor muscle strength were performed on 1, 21, 42 and 63 days after treatment. TGF-β1 was detected by ELISA, and TGF-β1 was detected by immunohistochemistry.

　　Results: On the 21 d after treatment, the TGF-β1 gene therapy group had better treatment effect in terms of maximum bladder capacity, leakage point pressure and contractility/muscle weight ratio, and there was no significant difference between the TGF-β1 gene therapy group and the electrical stimulation group. sex (P>0.05).

　　Conclusion: TGF-β1 gene therapy may become a new non-surgical treatment method, which can produce good effects on postpartum stress urinary incontinence model rats.